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BACKGROUND
Predict outcomes to decide choice of induction strategy: standard 
chemotherapy or “something else”
•  Quantify the role of various pre-treatment variables in the attainment of complete 
remission (CR) in elderly patients.
•  Validation of a hypothesized risk scoring 
system to predict remission outcomes in 
the elderly age group.
CONCLUSIONS & SUGGESTIONS
•  Our algorithm was statistically predictive of the remission outcomes after intensive chemotherapy in 
patients > 60 years of age.
•  A Treatment Failure Score (TFS) was constructed using six pre-treatment variables: Age, CD34 expression, 
NPM1 mutation status, Karyotype, Serum WBC and Serum LDH.
•  A TFS of > 2.2 was not only associated with a low likelihood of achieving remission (OR 4.75, P=0.0004) 
but also higher day 60 mortality (28% vs 10%)” in this elderly population receiving intensive chemotherapy
•  All components being available in ~7 days from diagnosis, will allow assignment of intensive vs less 
intensive (and toxic) therapy in this difficult patient population.
•  This approach will improve remission rates and hence survivorship.
•  Further refinement and validation of this approach may follow study of an increased sample size or ideally, 
a prospective study.
Not all Elderly “fit” Patients are “fit” for 
Intensive Chemotherapy: Results of ECOG 2906* Trial
...Is this good enough?
Attainment of remission is an important milestone in long term survivorship. 
An effective induction strategy is very crucial to achieve this milestone.
STUDY OBJECTIVES AND METHODS
The Data Source:
•  Retrospectively analyzed 95 elderly 
patients with AML treated with intensive 
chemotherapy at Penn State Hershey 
Medical Center from 2010-2015.
•  A TFS of > 2.2 was significantly associated with “no 
CR” with almost 5 times less likelihood of achieving CR.
•  A TFS of > 2.2 is also associated with a significantly 




A True Surrogate to Survival
The Predictors of Response
*Foran, J. M., Sun, Z., Claxton, D. F., Tallman, M. S. (2015). North American Leukemia, Intergroup 
Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and 
Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age 
≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood, 126(23), 217
@ 7+3, Daunorubicin and cytarabine
^ CRi, Remission with incomplete platelet recovery (<100,000)
Walter, Kantarjian et al, JCO 2010
 7+3@ Clofarabine
CR/CRi^ 43.8% 42.8%
Day 30 Mortality 8.5% 7.9%
Day 60 Mortality 14.9% 13.1%
Grade 3-4 Non Hematological Toxicity 27% 19%
INCLUDED EXCLUDED
7+3 Hypomethylating agents
CLAG/M Investigational agents on clinical trials
MEC Best supportive care
Clofarabine Promyelocytic leukemia
Cytarabaine Age <60 years
Treatment Failure Score (TFS) & Remission
TFS CRc (CR+CRi) No CR OR (95% CI)  (95% CI)
> 2.2






< 2.2 37 21
TOTAL 47 48
TOTAL PATIENTS, n=95
Multi-agent Chemo (88), Clofarabine (5), Ara-C (2)





































































(TFS) = A x B x C x D x E x F
 Variable
Hypothesized 
Odds Ratio (OR) 










































Based on Rollig et al, Blood 2010
